Patent Yard Sign in
Canadian application, no grantCanada

Sparing paclitaxel by the use of hyaluronan

CA 2208924 A1 · Owner: Hyal Pharmaceutical Corporation · Inventors: Moore, Adrian; Asculai, Samuel S.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

This invention relates to the use of forms of hyaluronan for use to deliver effective dosage amounts of the agent paclitaxel sold under the trade mark "Taxol" to a patient which medicine is present in a dosage amount much less than the usual amount presently being used when treating a patient with cancer.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed July 9, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 9, 2017.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2019.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 9, 1997
GrantedNo grant recorded
Term endedJuly 9, 2017
Patent numberCA 2208924 A1
Classification (IPC)A61K45/06 +1 more

Timeline

Timeline From CIPO dates

1998200020022004200620082010201220142016Application filedJuly 9, 1997Term endedJuly 9, 2017

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.